Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Imugene continues to actively enrol patients into the Phase 1b azer-cel trial at ten US sites with up to six sites in ...

In a new innovative and groundbreaking medical achievement, Abu Dhabi Stem Cells Centre (ADSCC) has manufactured the UAE's ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...

Outpatient CAR T therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.